CENTERS FOR DISEASE CONTROL



Epidemiologic Notes and Reports

- 589 Cryptosporidiosis: Assessment of Chemotherapy of Males with Acquired Immune Deficiency Syndrome (AIDS)
- 592 Rabies Mid-Atlantic States
- 594 Homicide United States
- 602 Urban Rat Control United States, Second Quarter, Fiscal Year 1982

# Cryptosporidiosis: Assessment of Chemotherapy of Males with Acquired Immune Deficiency Syndrome (AIDS)

Since December 1979, 21 males with severe, protracted diarrhea caused by the parasite, *Cryptosporidium*, have been reported to CDC by physicians in Boston, Los Angeles, Newark, New York, Philadelphia, and San Fransisco. All 21 have acquired immune deficiency syndrome (AIDS); 20 are homosexual; and one is a heterosexual Haitian. Their ages range from 23 to 62 years with a mean of 35.7 years. Most had other opportunistic infections or Kaposi's sarcoma in addition to cryptosporidiosis. Eleven had *Pneumocystis carinii* pneumonia (PCP); nine had Candida esophagitis; two had a disseminated *Mycobacterium avium-intracellulare* infection; one had a disseminated cytomegalovirus infection; and two had Kaposi's sarcoma. T-lymphocyte helper-to-suppressor ratios were decreased (< 0.9) in all 18 patients on whom this test was performed. Fourteen patients have died.

The illness attributed to *Cryptosporidium* was characterized by chronic, profuse, watery diarrhea. The mean duration of diarrhea was 4 months, often continuing until the patient's death. Bowel movement frequency ranged from six to 25 per day. The estimated maximum volume of stool during illness ranged from 1 to 17 liters per day with a mean of 3.6 liters per day. Diagnosis of cryptosporidiosis was made by histologic examination of small bowel biopsies (13 patients) or large bowel biopsies (four patients), or by stool examination using a sucrose concentration technique (16 patients) (1). More than one type of diagnostic method was positive for several patients.

Table 1 shows the drugs given to the 21 patients while they had diarrhea attributed to *Cryptosporidium*. Only two patients (9.5%) have had sustained resolution of their diarrhea with negative follow-up stool examinations. The first was being treated with prednisone (60 mg daily) for chronic active hepatitis at the time his diarrhea began. When cryptosporidiosis was diagnosed, he was started on diloxanide furoate (500 mg three times daily for 10 days), and the prednisone was tapered over 2 weeks and then stopped. Two weeks later, his diarrhea was improving; in another 2 weeks, his diarrhea had completely resolved. He has had no diarrhea for 8 months. Follow-up stool examinations 2 weeks and 6 weeks after discontinuation of diloxanide furoate were negative for *Cryptosporidium*.

The second patient, who also had a clinical and parasitologic response, subsequently died of PCP. In early February 1982, 6 months before his death, he had onset of watery diarrhea, and a small bowel biopsy showed *Cryptosporidium*. Treatment with furazolidone (100 mg four times a day) was initiated on May 5, and within 6 days, the patient had gained 1.1 kilograms (2.4 pounds); parenteral nutrition was discontinued, although he continued to produce a liter of watery stool each day. Ten days after treatment was started, his stools became formed for the first time in 4 months, but *Cryptosporidium* oocysts were still present. Furazo-lidone was increased to 150 mg four times daily. Twenty days after therapy was started (10

## U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES / PUBLIC HEALTH SERVICE

## Cryptosporidiosis – Continued

days after the higher dose of furazolidone was begun), the patient had one bowel movement a day, but his stool was still positive for *Cryptosporidium* and remained positive despite continued use of furazolidone at 150 mg four times daily for a total of 2 months. At that time, two stool examinations failed to detect oocysts, and the furazolidone was stopped. One week later, the patient developed PCP; despite treatment with trimethoprim-sulfamethoxazole, he died 2 weeks later on July 22. An autopsy was not permitted.

After various treatment regimens, seven patients have had partial or transitory decreases in their diarrhea. Two received no anti-parasitic drugs. A third patient temporarily improved after treatment with furazolidone (100 mg orally four times a day for 7 days), although 2 weeks elapsed between the end of treatment with furazolidone and the onset of clinical improvement. The patient's diarrhea abated, but follow-up stool examinations remained posi-

	Dose and route	Number of	Un	chan ged	Im	nproved <sup>§</sup>	Cured¶		
Drug*	of administration <sup>†</sup>	patients	n	(%)	n	(%)	n	(%)	
No treatment	-	2	0	(0.0)	2	(100.0)	0	(0.0)	
Trimethoprim/ sulfamethoxazole	25 mg/kg QID of sulfamethoxazole	7	7	(100.0)	0	(0.0)	0	(O.O)	
Trimethoprim/ sulfamethoxazole	800 mg PO BID of sulfamethoxazole	4	4	(100.0)	0	(0.0)	0	(0.0)	
Furazolidone	100 mg PO QID	6	4	(66.7)	1	(16.7)	1	(16.7)	
Furazolidone	300 mg PO QID	1	1	(100.0)	0	(0.0)	0	(0.0)	
Metronidazole	750 mg PO TID	5	4	(80.0)	1	(20.0)	0	(0.0)	
Metronidazole	750 mg IV TID	1	0	(0.0)	1	(100.0)	0	(0.0)	
Pyrimethamine/ sulfa	25 mg PO per day of pyrimethamine	4	4	(100.0)	0	(0.0)	0	(0.0)	
Diloxanide furoate	500 mg PO TID	3	2	(66.7)	0	(0.0)	1**	(33.3)	
Quinacrine	100 mg PO TID	3	3	(100.0)	0	(0.0)	0	(0.0)	
Diiodohydroxyquin	650 mg PO TID	2	2	(100.0)	0	(0.0)	0	(0.0)	
Tetracycline	500 mg PO QID	3	1	(33.3)	2	(66.6)	0	(0.0)	
Doxycycline	100 mg PO per day	2	2	(100.0)	0	(0.0)	0	(0.0)	
Pentamidine	4 mg/kg IM per day	2	2	(100.0)	0	(0.0)	0	(0.0)	
Chloroquine/ primaquine	500 mg PO per day of chloroquine	1	1	(100.0)	0	(0.0)	0	(0.0)	

## TABLE 1. Drugs used to treat males with cryptosporidiosis and AIDS

\*Some patients received more than one drug.

<sup>†</sup>BID = twice daily; TID = three times daily; QID = four times daily; PO = orally; IV = intravenously  $\frac{1}{2}$  Decrease in number of stools by at least 50%.

<sup>¶</sup>Absence of diarrhea for more than 2 weeks and stool examination negative for *Cryptosporidium*.

\*\*Improvement temporally related to stopping prednisone.

#### Vol. 31/No. 44

#### MMWR

## Cryptosporidiosis – Continued

tive for *Cryptosporidium*. Three months after furazolidone therapy, he again developed diarrhea, and his stools were positive for *Cryptosporidium*. Two patients had less diarrhea when given tetracycline. The first received tetracycline 500 mg orally four times a day for 4 months. His diarrhea decreased from 12 watery stools to three loose stools per day, but stool examination after 4 months of therapy still showed *Cryptosporidium*. The second patient, given the same treatment, also had a reduction in the number of stools. When the drug was discontinued, his diarrhea again increased.

Two patients' diarrhea stopped following treatment with opiates and metronidazole, given orally in one case and intravenously in the other. Neither patient had diarrhea after a few days of treatment, but both died within 1 week, and autopsies were not allowed. The first patient died from suspected peritonitis; the second died with disseminated Kaposi's sarcoma and pneumonia.

The remaining 12 patients have had continuous, severe diarrhea. In addition to the drugs listed in Table 1, bovine-transfer factor has been given to one patient and intravenous gamma globulin to two patients; neither was effective. At present, 14 (66.7%) of the 21 individuals have died, and six are alive with persistent diarrhea. In no instance was cryptosporidiosis thought to be the direct cause of death, but the associated severe malnutrition was often considered a contributing factor.

Shortly before cryptosporidiosis was recognized in AIDS patients, investigators at the U.S Department of Agriculture National Animal Disease Center (NADC) began testing drugs for efficacy against *Cryptosporidium* in animals; results of these initial studies were published in February, 1982 (2). More recently, five additional drugs have been evaluated at the NADC. Calves or pigs up to 14 days old without infection were given the drugs orally twice daily. One day after the drugs were started, each animal received a single oral inoculation of *Cryptosporidium*. The following drugs (with doses in mg/kg/day) were tested: amprolium (10.7), difluoromethylornithine (1250) plus bleomycin (6 IM), diloxanide furoate (125.0), dimetridazole (19.0), ipronidazole (23.8), lasalocid (0.7), metronidazole (23.8), monensin (4.8), oxytetracycline (50.0), pentamidine (10.0), quinacrine (11.9), salinomycin (6.0), sulfaquinoxaline (200.0), sulfadimidine (119.0), and trimethoprim (4.8) plus sulfadiazine (23.8). Although small numbers of animals were tested in each treatment group, no drugs prevented fecal shedding of oocysts or reduced the number of *Cryptosporidium* seen on intestinal biopsies.

Reported by J Goldfarb, MD, H Tanowitz, MD, Albert Einstein College of Medicine, Bronx, R Grossman, MD, Medical Arts Center Hospital, C Bonanno, MD, D Kaufman, MD, P Ma, PhD, St. Vincent's Medical Center, R Soave, MD, New York Hospital-Cornell Medical Center, D Armstrong, MD, J Gold, MD, Memorial Sloan-Kettering Cancer Center, S Dikman, MD, M Finkel, MD, H Sacks, MD, Mt. Sinai Medical Center, R Press, MD, New York University Medical Center, D William, MD, St. Luke's-Roosevelt Hospital, S Friedman, MD, New York City Dept of Health, R Rothenberg, MD, State Epidemiolgist, New York State Dept of Health; S Brown, MD, United Hospitals, Newark, WE Parkin, DVM, State Epidemiologist, New Jersey State Dept of Health; EJ Bergquist, MD, Thomas Jefferson University Hospital, Philadelphia, CW Hays, MD, State Epidemiologist, Pennsylvania State Dept of Health; P Forgacs, MD, Lahey Clinic Medical Center, Burlington, L Weinstein, MD, Brigham and Women's Hospital, Boston, NJ Fiumara, MD, State Epidemiologist, Massachusetts State Dept of Public Health; D Busch, MD, San Francisco, M Derezin, MD, M Gottlieb, MD, J Matthew, MD, W Weinstein, MD, UCLA Center for Health Sciences, J Chin, MD, State Epidemiologist, California Dept of Health Svcs; H Moon, PhD, National Animal Disease Center, Ames, Iowa; AIDS Activity, Div of Parasitic Diseases, Center for Infectious Diseases, CDC.

Editorial Note: *Cryptosporidium* is a protozoan parasite; it is a well recognized cause of diarrhea in animals, especially calves, but has only rarely been associated with diarrhea in humans (3). Individuals with normal immune function who have developed cryptosporidiosis have

## Cryptosporidiosis – Continued

self-limited diarrhea lasting 1-2 weeks, but immunosuppressed individuals have developed chronic diarrhea. An effective drug to treat cryptosporidiosis has not been identified, and the above reports are equally discouraging. Of seven patients who are still living, only one has no diarrhea at present. His recovery coincided with treatment with diloxanide furoate and discontinuation of prednisone. It seems unlikely that diloxanide furoate was responsible for his recovery, since three other patients who received the drug did not respond, and the drug was ineffective in experimentally infected pigs given nearly six times the recommended human dose. It is similarly difficult to be certain that improvement reported in other patients was due to the drugs they received because only a few patients receiving a drug responded, responses were brief, and the same or similar drugs were ineffective in preventing infection in experimental similarly infected preventing isolated responses is underscored by the two patients who improved before any specific therapy began.

Since none of the drugs reported above appears clearly efficacious, additional tests of other anti-parasitic drugs in animals are needed. Until an effective drug for cryptosporidiosis is identified or the underlying immune deficiency in patients with AIDS becomes correctable, management of diarrhea due to cryptosporidiosis will continue to focus on supportive care. *References* 

- 1. Anderson BC. Patterns of shedding of cryptosporidial oocysts in Idaho calves. J Am Vet Med Assoc 1981; 178:982-4.
- Moon HW, Woode GN, Ahrens FA. Attempted chemoprophylaxis of cryptosporidiosis in calves. Vet Rec 1982; 110:181.
- 3. CDC. Human cryptosporidiosis—Alabama. MMWR 1982; 31:252-4.

# **Rabies — Mid-Atlantic States**

An increased number of rabies cases among wild raccoons has recently been reported from the mid-Atlantic states (Maryland, Pennsylvania, Virginia, West Virginia) (Table 2). The disease is primarily concentrated in an eight-county area encompassing northern Virginia, western Maryland, and southcentral Pennsylvania (Table 3). One case has also been reported in Washington, D.C.

A single raccoon from eastern West Virginia was reported rabid in 1977—the first case in the area. Rabid raccoons were reported from contiguous counties in Virginia and West Virginia during 1978-1980; since then, the outbreak has grown to encompass several adjacent counties in Maryland and Pennsylvania. Between January 1 and October 15, 1982, 432 rabid raccoons had been reported from Virginia, 35 from Maryland, 23 from Pennsylvania, and 15 from West Virginia. Rabies among dogs and cats has also been reported. The first case of

	1977	1978	1979	1980	1981	1982
Maryland	0	0	0	0	7	35
Pennsylvania	0	0	0	0	0	23
Virginia	0	3	4	7	102	432
West Virginia	1	0	8	14	22	15
U.S. total				394	481	700

TABLE	2.	Raccoon	rabies –	mid-Atlantic states
-------	----	---------	----------	---------------------

\*Through October 15, 1982

rabies in a raccoon in Washington, D. C., was reported on October 27, 1982. Within the raccoon-outbreak area, rabid skunks, bats, and foxes have been reported during the last 12 months (Table 4).

Reported by E Israel, MD, State Epidemiologist, Maryland State Dept of Health and Mental Hygiene; CW Hays, MD, State Epidemiologist, Pennsylvania State Dept of Health; GB Miller, Jr, MD, State Epidemiologist, Virginia State Dept of Health; LE Haddy, MS, State Epidemiologist, West Virginia State Dept of Health; ME Levy, MD, State Epidemiologist, District of Columbia Dept of Human Svcs; Viral and Rickettsial Zoonoses Br, Div of Viral Diseases, Center for Infectious Diseases, CDC.

**Editorial Note:** The pattern of rabies among raccoons in the mid-Atlantic states represents a significant departure from the pattern seen in the United States during the last 10 years. In most of the country, raccoon rabies occurs as sporadic, isolated cases. However, in the south-eastern states—Alabama, Florida, Georgia, and South Carolina—raccoons are the major rabies reservoir, and raccoon rabies occurs as an enzootic or epizootic disease. As recently as 1980, 90% of all raccoon rabies in the United States was reported from these four states; Georgia alone reported 208 cases (53% of the total that year). So far in 1982, Virginia has reported 62% of all raccoon rabies in the United States. Thus, in a two-year span, Virginia has reported a > 60-fold increase in raccoon rabies.

Local, state, and federal health agencies are cooperating to study the spread of the outbreak by intensifying rabies surveillance activities in the affected areas. Health agencies are also cooperating to educate the public to the risk of exposure to wild animals in rabiesaffected areas, to the necessity for keeping rabies immunizations for pet dogs and cats current, and to the importance of seeking medical attention if bitten or exposed to wild animals.

There is no known technique for effectively eliminating rabies in wildlife, but research concerning the understanding and control of the disease in wild animal populations is underway. No human rabies case has ever been known to result from a raccoon bite.

MARYLAND		VIRGINIA	
Allegheny	25	Loudoun	212
Montgomery	5	Fairfax	138
Washington	5	Fauquier	34
Total	35	Prince William	33
		Culpeper	6
PENNSYLVANIA		Frederick	4
Bedford	17	Arlington	2
Bucks	2	Augusta	1
Montgomery	3	Rockingham	1
Sullivan	1	Madison	1
Total	23	Total	432

TABLE 3. Raccoon rabies by county, January 1-October 15, 1982 — mid-Atlantic states

TABLE 4. Animal rabies, January 1-October 15, 1982 - Maryland, Virginia

	MARYLAND	VIRGINIA
Raccoons	35	432
Skunks	6	35
Bats	17	9
Foxes	1	11
Dogs	0	2
Cats	0	8
Other	1*	6†

\*cow

<sup>†</sup>5 groundhogs, 1 ferret

# Perspectives in Disease Prevention and Health Promotion

# Homicide — United States

In 1981, the Federal Bureau of Investigation's Uniform Crime Reporting System (FBI-UCR) estimated that 22,516 instances of homicide occurred in the United States (1).\* The rate was 9.8 per 100,000 population, representing a 3.9% decrease from the 1980 homicide rate. An estimated 591,007 potential years of working life were lost in 1981 due to homicide (2).

From 1977 to 1980, the homicide rate gradually increased, but since the end of 1980, the trend has leveled off (1). As in previous years, the South experienced the highest homicide rate—13 homicides per 100,000 population. The West had a rate of 10/100,000, while the Northeast and the North Central region had homicide rates of approximately 8 and 7/100,000, respectively (1).

In 1981, the FBI-UCR estimated that 77% of homicide victims were male. Approximately 54% were white, 44% black, and 2% of other races. Fifty-nine percent were less than 35 years of age (1).

#### (Continued on page 600)

\*Homicide is defined as the willful (non-negligent) killing of one human being by another, but does not include justifiable homicide, which is the killing of a felon by law enforcement officers in the line of duty or by private citizens.

	4	4th Week End	ing	Cumu	lative, First 44 V	Veeks
Disease	November 6, 1982	November 7 1981	Median 1977-1981	November 6, 1982	November 7, 1981	Median 1977-1981
Aseptic meningitis	260	211	211	7.624	8.243	6.580
Brucellosis	3	2	2	140	143	153
Encephalitis: Primary (arthropod-borne						
& unspec.)	25	33	27	1,205	1.271	1.020
Post-infectious	4	1	3	54	80	186
Gonorrhea: Civilian	18,962	20.158	20.510	809.053	852,145	850,236
Millitary	396	552	552	22,340	23,789	23,221
Hepatitis: Type A	411	429	575	18,962	21,201	24,737
Type B	416	387	340	18.026	17,264	13,889
Non A. Non B	57	N	N	1,937	N	N
Unspecified	148	192	192	7,482	9,136	8,752
Legionellosis	4	Ň	N	438	N	N
Leprosy	4	1	2	169	215	149
Malaria	9	26	17	895	1.210	645
Measles (rubeola)	8	14	89	1.499	2,753	13,104
Meningococcal infections: Total	51	39	39	2.477	2.965	2,205
Civilian	51	39	39	2,464	2,954	2,185
Military				13	11	16
Mumps	71	96	176	4,562	3,751	12,017
Pertussis	29	21	34	1,415	1.060	1.456
Rubella (German measles)	27	18	46	2,138	1.883	11.053
Syphilis (Primary & Secondary): Civilian	655	717	502	27.849	26,181	21.056
Military	13	4	4	379	329	264
Tuberculosis	525	552	547	21,704	22.933	23,292
Tularemia	525	552	5	225	236	173
Typhoid fever		10	10	339	505	442
Typhus fever, tick-borne (RMSF)	9	10	8	947	1.144	1.080
Rabies, animal	112	105	75	5,327	6,341	4,376

#### TABLE I. Summary-cases of specified notifiable diseases, United States

#### TABLE II. Notifiable diseases of low frequency, United States

982 Cum. 1982
Poliomyelitis: Total 4 Paralytic 4 Psittacosis (Ariz. 1) 103 Rabies, human - Tetanus 68 Trichinosis (Md. 1) 78 Tyohus fever, flea-borne (endemic. murine) 38
Trichinosis (Md. 1) Typhus fever, flea-bor

			Novem	ber 6, 19	982 and N	ovember 7,	1981 (4	4th we	ek)			
	Aseptic		Encer	ohalitis			н	lepatitis (V	/iral), by ty	pe	Legionel-	
Reporting Area	Menin- gitis	Brucel- losis	Primary	Post-in- fectious		orrhea vilian)	A	В	NA,NB	Unspeci- fied	losis	Leprosy
	1982	Cum. 1982	Cum. 1982	Cum. 1982	Cum. 1982	Cum. 1981	1982	1982	1982	1982	1982	Cum. 1982
UNITED STATES	260	140	1,205	54	809,053	852,145	411	416	57	148	4	169
NEW ENGLAND	22	3	50	6	19,569	20,903	5	14	2	9	-	1
Maine N.H.	3 3	-	- 8	-	1,008 644	1,126 762	1	-	-	-	-	-
Vt.	-	-	-	-	367	374	-	-	Ē	-	-	-
Mass.	3 5	-	20	1	8,767 1,308	8,821 1,238	1	5 2	1	9		-
R.I. Conn.	8	3	22	5	7,475	8,582	2	7	1	-	-	1
MID. ATLANTIC	37	3	120	14	102,947	102,782	71	87	5 1	13 3	1	9 1
Upstate N.Y. N.Y. City	13 6	3	50 17	3	17,092 41,915	17,890 42,040	14 17	16 23	-	3	-	6
N.J.	8	-	21	-	18,940	19,459	11	20	4	3 4	1	1
Pa.	10	-	32	11	25,000	23,393	29	28	-		-	
E.N. CENTRAL	50 25	4 1	307 116	10 4	111,366 30,893	127,021 39,942	31 17	46 21	1	7 5	1	7
Ohio Ind.	25	-	83	3	13,924	10,736	4	3	-	-	-	-
HI.	1	2	15	1	28,578	36,735 27,985	3 7	2 20	-	1	-	6
Mich. Wis.	18	1	64 29	2	27,705 10,266	11,623	-	- 20	-	-	-	1
W.N. CENTRAL	7	16	87	4	38,152	40,994	9	16	-	2	-	5 3
Minn.	4	1 5	27 43	1	5,554 4,035	6,515 4,525	2	1	-	1	-	-
lowa Mo.	1	4		-	18,145	18,962	-	5	-	1	-	1
N. Dak.	-	1	-	1	498 1,009	517 1,098	-	-	-	-	-	1
S. Dak. Nebr.	2	2	5	-	2,306	3,040	-	5	-	-	-	-
Kans.	-	3	5	1	6,605	6,337	7	4	-	-	-	-
S. ATLANTIC	42	25	178	8	213,113 3,570	209,772 3,351	51 1	77	13	13 1	2	10
Del. Md.	3	-	22		26,473	25,033	ż	11	3	2	-	3
D.C. Va.	2	8	35	1	12,899 17,077	11,841 19,249	-	8	2	2	-	1
W. Va.	1	-	16	-	2,368	3,157	2	2	1	-	-	-
N.C.	9 1	2	26 2	1	33,883 20,582	32,437 20,383	4	8 7	-	2	-	-
S.C. Ga.	i	3	14	-	41,577	43,505	12	15	1	2	-	1
Fla.	25	12	63	6	54,684	50,816	23	26	6	3	2	5
E.S. CENTRAL	6	12	60 1	2	70,545 9,499	71,094 8,806	16 5	13 2	2 1	1	-	-
Ky. Tenn.	3	7	27		27,863	26,839	6	6	1	-	-	-
Ala. Miss.	3	4	16 16	2	20,579 12,604	21,660 13,789	1	4	-	1	:	· -
	-						88	39	1	62		26
W.S. CENTRAL Ark.	24	44	188 16	1	112,641 9,105	112,345 8,515	-	4	-	4	-	26
La.	9	8	24	-	21,027	19,575	29 9	12 8	1	18	-	-
Okla. Tex.	4 11	7 22	35 113	1	12,275 70,234	12,247 72,008	50	15	-	5 35	-	26
MOUNTAIN	19	3	41	3	27,576	33,468	28	23	7	8	-	2
Mont.	1	2	-	-	1,142	1,241 1,498	1	2	-	-	-	-
ldaho Wyo.	3	1	-	-	1,324 832	861	i	1	-	-	-	1
Colo.	2	-	19	1	7,329	9,012	6	8	-	-	-	-
N. Mex. Ariz.	1		11	-	3,777 7,275	3,726 9,871	4 12	3	- 5	ż	-	-
Utah	12	-	5	2	1,342	1,665	3	3	1	-	-	1
Nev.	-	-	5	-	4,555	5,594	1	2	1	1	-	-
PACIFIC Wash	53 5	30 1	174 12	6	113,144 9,726	133,766 11,247	112 2	101 2	26	33 5	-	109
Oreg.	5	-	4	-	6,724	7,974	10	3	1	1	-	8 1
Calif. Alaska	40	28 1	144 10	6	91,607 2,908	108,478 3,459	99 1	90 5	25	27	-	69
Hawaii	3	-	4	-	2,508	2,608	-	1	-	-	-	1 30
Guam	U	-	-	-	104	98	U	U	U	U	U	1
P.R. V.I.	-	-	1	3	2,268 207	2,758 198	-	-	-	-	-	1
Pac. Trust Terr.	Ū	-	-	-	207	379	Ū	Ū	Ū	Ū	Ū	13

## TABLE III. Cases of specified notifiable diseases, United States, weeks ending November 6, 1982 and November 7, 1981 (44th week)

N: Not notifiable

U: Unavailable

UNITED STATES NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	Ma 1982 9 1 - - 1 1	laria Cum. 1982 895 44 - 2 - 2 4 3 15	1982 8 1 - -	easles (Ru Cum. 1982 1,499 16 3	ubeola) Cum. 1981 2,753 83	Infe	ococcal ctions otal) Cum. 1982	Mu 1982	mps Cum.	Pertussis		Rubella Cum.	Cum.
UNITED STATES NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	9 1 - - 1 1	1982 895 44 - 2 - 24 	8 1 - -	1982 1,499 16	1981 2,753			1982				Cum	Cum.
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	1 - - 1 1	44 2 24 3	1	16		51			1982	1982	1982	1982	1981
Maine N.H. Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	- - 1	2 24 3	-	-	83		2,477	71	4,562	29	27	2,138	1,883
N.H. Vt. Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	- - 1 1	24 3	-	3	5	3	130 9	2	188 41	-	4	24	119 33
Mass. R.I. Conn. MID. ATLANTIC Upstate N.Y.	1 1	3	-	2	6	2	17	1	18	-	-	10	33 51
Conn. MID. ATLANTIC Upstate N.Y.	1 1		1	5	59	-	10 32	-	86	-	3	8	23
Upstate N.Y.			-	6	10	-	16 46	i	16 20	-	1	1 5	12
opstate N. F.		149 27	2	168	868	8	445	9	302	5	1	103	222
N.Y. City	-	57	1	117 42	212 88	3 2	153 89	5	80 47	3	1	49 35	107 55
N.J. Pa.	1	31 34	1	5 4	58 510	2 1	89 114	4	47 128	1	2	18 1	47 13
E.N. CENTRAL	1	81	-	77	81	8	311	22	2,290	6	1	186	398
Ohio Ind.	1	13 3	:	1	16 9	4 1	112 31	4 3	1,598 40	4	-	29	3
III.	-	34	-	24	23	1	77	2	195	1	1	29 69	135 103
Mich. Wis.	-	26 5	-	50	30 3	2	74 17	8 5	338 119	1	-	49 39	37 120
W.N. CENTRAL	2	24	-	49	10	3	119	9	589	9	1	60	79
Minn. Iowa	-	2 7	:	-	3 1	1	31 12	4	447 35	9	1	6	8
Mo.	2	8	-	2	i	1	30	i	19	-	-	38	4
N. Dak. S. Dak.	2	1	2	-	-	-	6 6		- 1	-	-	ĩ	-
Nebr. Kans.	2	3 3	-	3 44	4	1	14 20	1 2	1 86	-	-	15	1 64
S. ATLANTIC	-	123	-	110	453	15	523	3	280	4	3	88	139
Del. Md.	-	4	-	3	-	-	-	-	12	-	-	1	1
D.C.	-	19 4	-	1	5 1	2	36 4	-	30	-	:	34	1
Va. W. Va.	-	39 7	2	14 3	9	2	63 9	1	38	1	-	13	6
N.C. S.C.	-	7	-	1	3	1	101	i	97 20	i	1	2	22 5
Ga.	-	4 16	-		2 111	1 3	61 104	1	17 20	-	1	1 16	8 37
Fla.	-	23	-	88	313	6	145	-	46	1	i	19	59
E.S. CENTRAL Ky.	-	9 5	-	9 1	5 1	2	150 25	2 1	57 19	-	-	46 28	37
Tenn. Ala.	-	-	-	6	2	2	66	-	22	-	-	20	23 13
Miss.	-	1 3	-	2	2	-	48 11	1	9 7	-	-	16	1
W.S. CENTRAL	-	61	3	155	868	4	291	2	213	1	2	117	169
Ark. La.	-	4 5	-	2	22 4	-	14 61	-	7 6	-	:	1	3 9
Okla. Tex.	-	8 44	3	30 123	6 836	1 3	28 188	2	200	1	2	3	2
MOUNTAIN	1	30		28	35	3	109	2	102	2	2	112	155
Mont.	-	1	-	-	-	1	6		4	-	2	80 5	94 3
ldaho Wyo.	-	2	-	ī	1	-	75	-	4	-	-	6 7	4
Colo. N. Mex.	-	12	-	ż	10	2	46	1	17	2	-	6	12 30
Ariz.	1	3 8	-	17	8 5	:	15 19	- 1	48	-	2	6 16	5
Utah Nev.	2	4	-	3	10	-	9	-	20 7	-	-	22 12	21 8
PACIFIC	3	374	2	887	350	5	399	20	, 541	2	13	1,434	11
Wash.	2	23	-	42	3	-	48	20	71	1	13	1,434	626 91
Oreg. Calif.	1	14 332	2	23 816	5 335	- 5	74 262	13	440	1	12	6	53
Alaska Hawaii	-	1 4		1	7	-	11	4	10	-	13	1,376	466 1
		4	- U	6	6	-		-	20	-	-	9	15
Guam P.R.	U -	4	-	132	288 24	U -	2 8	U -	3 78	U -	U -	2 11	2 4
V.I. Pac. Trust Terr.	Ū	-	Ū	-	24	Ū	2	Ū	3 5	Ū	Ū	-	1

TABLE III. (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending November 6, 1982 and November 7, 1981 (44th week)

U: Unavailable

	Syphilis (Primary &		Tuber	rculosis	Tula- remia	Typi Fev	noid ver	(Tick-	s Fever borne) ASF)	Rabies, Animal
Reporting Area	Cum. 1982	Cum. 1981	1982	Cum. 1982	Cum. 1982	1982	Cum. 1982	1982	Cum. 1982	Cum. 1982
UNITED STATES	27,849	26,181	525	21,704	225	4	339	9	947	5,327
NEW ENGLAND	500	500	11	606	6	-	17	1	11	41
Maine	7	5 12	-	51 23	-	-	-	-	1	26 1
N.H. Vt.	1	16	-	13	-	-	2	-	-	2
Mass.	338	322	10	385	6	:	13	1	6 2	6
R.I. Conn.	21 129	30 115	1	26 108	-	-	2	-	2	6
MID. ATLANTIC	3.760	3,744	65	3,650	7	2	63	1	44	187
Upstate N.Y.	387	361	8	623	7	:	9	1	16 3	102
N.Y. City N.J.	2,225 549	2,222 525	39 5	1,417 707	-	1	34 12	-	13	17
Pa.	599	636	13	903	-	-	8	-	12	68
E.N. CENTRAL	1,555	1,984	106	3,303	1	-	30	-	84	539 75
Ohio Ind.	264 174	265 260	10	546 397	-	-	11 2	2	76 2	70
Ma.	774	1,059	67	1,439	-	-	5	-	6	279
Mich.	257 86	323	25	742	1	-	9 3	-	-	6 109
Wis.			-	179		-		-		
W.N. CENTRAL	471 109	576 173	12	635 107	34	-	16 8	-	33	1,091 185
Minn. Iowa	29	24		66	2	-	ĭ	-	4	352
Mo.	261	328	12	313	22	-	4	-	12	112
N. Dak.	7	9 2		13 27	1	-	-	-	4	90 95
S. Dak. Nebr.	14	9	-	26	4	-	2	-	2	116
Kans.	49	31	-	83	5	-	1	-	11	141
S. ATLANTIC	7,674	6,988	124 2	4,516 42	12	-	40	2	508	1,040 2
Del. Md.	20 416	13 506	22	523	1		9	-	49	53
D.C.	405	565	19	227	:	-	-	1	72	564
Va. W. Va.	525 26	600 23	12	487 133	4	-	3 4		8	39
N.C.	624	556	12	676	-	-	2	-	218	65
S.C.	474 1.592	482 1.714	8 15	429 725	6	-	3	-	105 50	64 188
Ga. Fla.	3,592	2,529	33	1,274	1	-	19	1	6	65
E.S. CENTRAL	1,924	1,706	47	1,984	8	-	19	4	92	591
Ky.	114	91	22	532	6	-	4 3	3	1 59	122 329
Tenn. Ala.	540 730	613 511	8 15	640 535	-		9	-	15	133
Miss.	540	491	2	277	2	-	3	1	17	7
W.S. CENTRAL	7,350	6,303	48	2,615	117	1	35	!	156	1,025
Ark. La	180 1,630	133 1,432	57	308 391	71 3	-	5 3	1	22 2	141 31
Okla.	154	150	12	291	33	-	3	-	76	176
Tex.	5,386	4,588	24	1,625	10	1	24	-	56	677
MOUNTAIN	713	647	10	599	30 4	1	14	-	13	265
Mont. Idaho	5 25	11 18	1	38 28	4	-	-	-	4	85 10
Wyo.	16	16	-	6	5	-	-	-	1	21
Colo.	187	192	5	77 101	7	-	3	-	1	48
N. Mex. Ariz.	168 197	113 159	3	249	-	1	8	-	1	23 56
Utah	20	25	-	40	11	-	2	-	:	18
Nev.	95	113	1	60	•	-	1	-	2	4
PACIFIC Wash	3,902	3,733	102 5	3,796 232	10 1	-	105	-	6	548
vvasn. Oreg.	128 93	162 100	11	165	2	-	6 4	-	1	8 3
Calif.	3,572	3,398	85	3,088	6	-	91	-	5	458
Alaska Hawaii	14 95	11 62	1	74 237	1	-	1 3	-	-	79
Guam	1		U	36	_	U	•		-	-
				383	-	0	2	U	-	-
P.R. V.I.	672 22	559 16	1	303	-	-	2	-	-	45

# TABLE III. (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending November 6, 1982 and November 7, 1981 (44th week)

U: Unavailable

TABLE IV. Deaths in 121 U.S. cities,* week ending
November 6, 1982 (44th week)

		All Cause	es, By Ag	je (Years	s)					All Cau	ses, By A	Age (Yea	rs)		
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I** Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I** Total
NEW ENGLAND	699	473	161		16	12	57	S. ATLANTIC	1,009	666	213	67	28	33	27
Boston, Mass.	194 58	118 37	56 14	9 6	5	6 1	25 4	Atlanta, Ga.	132 101	75 59	28 29	18 8	6 3	5 2	2
Bridgeport, Conn. Cambridge, Mass.	26	21	5	-	-	-	3	Baltimore, Md. Charlotte, N.C.	65	37	15	9	2	2	2
Fall River, Mass.	29	22	5	2	-	-	-	Jacksonville, Fla.	93	66	17	ă,	5	ī	-
Hartford, Conn.	47	28	14	2	-	3	1	Miami, Fla.	83	58	20	2	1	2	2
Lowell, Mass.	21	17	3	1	-	-	2	Norfolk, Va.	63	32	23	4	-	4	4
Lynn, Mass.	12 s. 29	10 19	2 9	-	1	:	2 1	Richmond, Va.	85	44	27	6	2	6	5
New Bedford, Mas New Haven, Conn.	s 29 69	46	17	4	1	1	2	Savannah, Ga. St. Petersburg, Fla.	63 93	40 77	11 12	6 1	5 2	1	3
Providence, R.I.	62	41	14	4	3		7	Tampa, Fla.	68	44	18	3	2	3	2
Somerville, Mass.	12	8	3	1	-	-	1	Washington, D.C.		108	1	4	2	5	2
Springfield, Mass.	46	32	9	3	2	-	5	Wilmington, Del.	41	26	12	2	-	1	-
Waterbury, Conn.	37	29	5	1	2		2								
Worcester, Mass.	57	45	5	4	2	1	2	E.S. CENTRAL	660	413	168	42	17	20	30
MID. ATLANTIC	2,568	1.699	567	169	65	66	112	Birmingham, Ala. Chattanooga, Tenn	104	61 30	24	8	4	7	3
Albany, N.Y.	62	42	11	1	-	8		Knoxville, Tenn.	51	30	12 8	17	1	2	3
Allentown, Pa	25	22	2	1	-	-	-	Louisville, Ky.	97	64	25	4	1	3	2 9
Buffalo, N.Y.	155	100	37	12	3	3	24	Memphis, Tenn.	169	111	40	12	ż	4	6
Camden, N.J.	33 30	29 19	3	-	1	-	-	Mobile, Ala.	38	26	9	1	2	-	ĭ
Elizabeth, N.J. Erie, Pa.†	30	27	11 6	1	-	5	2	Montgomery, Ala.	46	27	13	2	2	2	-
Jersey City, N.J.	43	28	6	5	-	4	1	Nashville, Tenn.	111	60	37	7	5	2	6
N.Y. City, N.Y.	1,369	924	284		38	27	43	W.S. CENTRAL	1.083	650	259	~ 1	- 4	••	
Newark, N.J.	67	35	20	8	1	2	5	Austin, Tex.	44	23	259	91 2	51	32	42
Paterson, N.J.	27	15	7	2	-	3	2	Baton Rouge, La	40	30	7	2	3	1	1
Philadelphia, Pa.†	301 75	185 43	76 26		12	10	19	Corpus Christi, Tex		24	9	ī	2		1
Pittsburgh, Pa.† Reading, Pa.	28	43 24	26	6 1	-	-	3 2	Dallas, Tex.	191	121	44	10	11	5	ż
Rochester, N.Y.	112	76	26	ż	2	1	7	El Paso, Tex. Fort Worth, Tex.	59	35	17	4	-	3	7
Schenectady, N.Y.	33	18	10	3	2	2	í	Houston, Tex.	78 171	51	19	5	1	2	6
Scranton, Pa.†	25	15	8	-	2	-	-	Little Rock, Ark.	59	88 31	46 20	20 5	13	4	3
Syracuse, N.Y.	67	45	13	4	2	з	-	New Orleans, La.	116	71	19	11	9	3 6	4
Trenton, N.J. Utica, N.Y.	23 27	14 19	7	2	-	-	1	San Antonio, Tex.	137	92	24	16	4	1	1 6
Yonkers, N.Y.	27	19	6 5	1 1	1 1	2	2	Shreveport, La. Tulsa, Okia.	76 76	40 44	20 19	10	35	3	4
		1,406			63	94	87	MOUNTAIN	606	376	144	45			3
Akron, Ohio Canton, Ohio	82 34	50	21	6	2	3	2	Albuquerque, N.Me	ex. 94	56	26		24 1	17	26 1
Chicago, III	503	31 311	3 126	29	15	22	4	Colo. Springs, Colo		19	8	ź	ż	-	2
Cincinnati, Ohio	142	94	37	29	2	4	14 18	Denver, Colo.	113	73	23	7	7	3	6
Cleveland, Ohio	158	98	32	16	2 2	10	2	Las Vegas, Nev. Ogden, Utah	68 29	36	17	12	2	1	3
Columbus, Ohio	91	64	18	2	3	4	4	Phoenix, Ariz.	138	21 83	4 35	2	-	2	3
Dayton, Ohio Detroit, Mich.	127	68	42	5	5	7	6	Pueblo, Colo.	21	14	35	11	7	2	-
Evansville, Ind.	252 29	159 23	56 4	17 1	7	13	9	Salt Lake City, Uta	h 37	19	14	3	2	2	1
Fort Wayne, Ind.	49	38	7	3	1	ī	2 3	Tucson, Ariz.	75	55	14	ĩ	3	ż	9
Gary, Ind.	18	9	5	3	1		-	PACIFIC	1 75 0						-
Grand Rapids, Micl		36	10	1	-	3	3	Berkeley, Calif.	1,756 18	1,127 14	378	121	69	59	66
Indianapolis, Ind. Madison, Wis.	182	116	42	4	13	7	3	Fresno, Calif.	76	52	14	1		-	:
Milwaukee, Wis.	37 132	18 99	10	5	1	3	5	Glendale, Calif.	30	23	3	3	1	6 1	2
Peoria, III.	52	28	21 12	5 6	4 1	3 5	4	Honolulu, Hawaii	42	19	14	ž	4	3	2 3
Rockford, III	33	18	10	3	ź	Э	4	Long Beach, Calif.	87	46	23	6	Ğ	6	1
South Bend, Ind.	31	18	10	1	-	2		Los Angeles, Calif. Oakland, Calif.	556 56	351	124	44	24	11	15
Toledo, Ohio	105	70	25	4	3	3	2	Pasadena, Calif.	21	38 16	12	3	-	3	1
Youngstown, Ohio	89	58	23	3	1	4	1	Portland, Oreg.	123	84	2 29	3 5	i	-	2
W.N. CENTRAL	773	544	161	31	16	21		Sacramento, Calif.	61	43	14	1	2	4	3 6
Des Moines, Iowa	57	47	9	-	-	21	32	San Diego, Calif.	114	72	26	8	3	5	10
Duluth, Minn.	34	20	12	1	-	i	3	San Francisco, Cal San Jose, Calif		95	31	15	4	5	2
Kansas City, Kans.	26	16	5	1	3	1	1	Seattle, Wash	151	93	30	10	10	8	6
Kansas City, Mo. Lincoln, Nebr.	140 26	97	33	5	1	4	ż	Spokane, Wash	147 74	97 43	24	14	9	3	4
Minneapolis, Minn.	26 94	17 63	6 17	1 6		2	-	Tacoma, Wash	50	43	22	3	3 2	3	7
Omaha, Nebr.	81	58	14	8	3 1	5	5					-	2	-	2
	149	104	34	5	5	ī	4	TOTAL	11,350	7,354	2.565	722	349	354	479
St. Louis, Mo.		104	34	5						+	2,505	122	349		
St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	72	61 61	8 23	- 4	5 - 3	3	5			1,004	2,505	122	349	354	4/9

Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not

\*\* Pneumonia and influenza

Finanticina and interaction in reporting methods in these 4 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

th Total includes unknown ages. § Data not available. Figures are estimates based on average of past 4 weeks.



Years of potential Estimated mortality Cause of life lost before June 1982 Estimated number morbidity or mortality age 65 by persons Annual of physician contacts (Ninth Revision ICD, 1975) dying in 1980<sup>1</sup> Number<sup>2</sup> Rate/100.0003 June 1982<sup>4</sup> ALL CAUSES (TOTAL) 10,006,060 157,164 826.7 101.397.000 Accidents and adverse effects (E800-E807, E810-E825, 2.684.850 E826-E949) 8.251 43.4 5.936.000 Malignant neoplasms (140-208)1,804,120 35.512 186.8 1,544,000 Diseases of heart (390-398. 1.636.510 58.630 308.4 5.909.000 402.404-429) Suicides, homicides 1,401,880 4 01 1 21.1 (E950-E978) Chronic liver disease and cirrhosis (571) 301.070 2.110 11.1 158.000 Cerebrovascular diseases 63.6 725.000 (430-438) 280.430 12.091 Pneumonia and influenza<sup>5</sup> 716.000 124,830 3,555 18.7 (480-487) **Diabetes mellitus** (250)117.340 2.643 13.9 2.503.000 Chronic obstructive pulmonary diseases and allied conditions 5.114 26.9 1.014.000 110,530 (490-496) Prenatal care<sup>6</sup> 3,310,000 Infant mortality<sup>6</sup> 3.200 10.6 /1,000 live births

TABLE V. Years of potential life lost, deaths, and death rates, by cause of death, and estimated number of physician contacts, by principal diagnosis, United States

<sup>1</sup>Years of potential life lost for persons between 1 year and 65 years old at the time of deathare derived from the number of deaths in each age category as reported by the National Center for Health Statistics, *Monthly Vital Statistics Report* (MVSR), Vol. 29, No. 13, September 17, 1981, multiplied by the difference between 65 years and the age at the midpoint of each category. As a measure of mortality, "Years of potential life lost" underestimates the importance of diseases that contribute to death without being the underlying cause of death.

<sup>2</sup>The number of deaths is estimated by CDC by multiplying the estimated annual mortality rates (MVSR Vol. 31, No. 7, October 7, 1982, pp. 8-9) and the provisional U.S. population in that month (MVSR Vol. 31, No. 6, September 9, 1982, p.1) and dividing by the days in the month as a proportion of the days in the year.

<sup>3</sup>Annual mortality rates are estimated by NCHS (MVSR Vol. 31, No. 7, October 7, 1982, pp. 8-9), using the underlying cause of death from a systematic sample of 10% of death certificates received in state vital statistics offices during the month and the provisional population of those states included in the sample for that month.

<sup>4</sup>IMS America *National Disease and Therapeutic Index* (NDTI), Monthly Report, June 1982, Section III. This estimate comprises the number of office, hospital, and nursing home visits and telephone calls prompted by each medical condition based on a stratified random sample of office-based physicians (2,100) who record all private patient contacts for 2 consecutive days each quarter.

<sup>5</sup>Data for "infectious diseases and their sequelae" as a cause of death and physician visits comparable to other multiplecode categories (e.g., "malignant neoplasms") are not presently available.

<sup>6</sup>"Prenatal care" (NDTI) and "Infant mortality" (MVSR Vol. 31, No. 6, September 9, 1982, p.1) are included in the table because "Years of potential life lost" does not reflect deaths of children <1 year.</p>


## Homicide - Continued


Using homicide statistics for 1978, 1979, and 1980, life expectancy statistics for 1978, and population counts for 1980, the FBI-UCR calculated the probability of homicide victimization (1). A U.S. citizen's chance of becoming a homicide victim is 1 out of 153. Males have a 1/100 chance of becoming a victim, while females have a 1/323 chance. White persons have a 1/240 chance compared with a 1/47 chance for persons of other races (1).

Of all homicides reported to the FBI-UCR between 1976 and 1979, 19% were committed by members of the victims' families, 39% by acquaintances, and 13% by strangers; offenders were unidentified in 29%. Children less than 10 years old were generally the victims of family members; acquaintances were the most likely offenders of victims 10 to 59 years old; and offenders of victims  $\ge 60$  were most likely to remain unidentified (Figure 1).

From 1976 to 1979, 47% of all homicides were precipitated by an argument, 1% involved a gang fight, 2% involved sexual assault, and 15% occurred during commission of another crime; miscellaneous non-felony circumstances accounted for 16% of homicides, and the circumstances were undeterminable in 20%. For victims under age 15, miscellaneous non-felony circumstances accounted for the greatest proportion of homicides. For victims 15 to 74 years of age, the precipitating circumstance usually involved an argument. For victims age 75 and older, homicides were most likely to occur during the commission of another crime (Figure 2).

In 1981, 50% of homicides were committed with handguns, 13% with rifles or shotguns, and 19% with cutting or stabbing instruments. The remaining 18% were committed with clubs, poison, hands, fists, feet, or other means (1).





AGE GROUP (YEARS)

\*These data represent the distributions of the relationship between the first specified victim and the first specified offender reported for each homicide incident.

†Based on 69,890 homicides, excluding 1,041 first specified victims of unknown age.


### Vol. 31/No. 44


Homicide - Continued

Reported by Office of the Center Director, Center for Health Promotion and Education, CDC.

Editorial Note: Because the majority of homicides in 1981, as in previous years, were committed by relatives or acquaintances of the victims, the report states that "criminal homicide is primarily a societal problem over which law enforcement has little or no control," and suggests that homicides that do not occur during the commission of other crimes defy the traditional prevention and deterrence strategies of law enforcement agencies. This suggests that those acts of violence unrelated to other criminal activity are most immediately in need of public health prevention and intervention strategies (3). The foundations for medical and public health involvement in this problem have already been laid through work on family violence (3-7). Potential homicide prevention strategies include: a) educational programs focused on conflict and stress management for children and adults, b) promotion of neighborhood ties, c) the design of structurally safe environments, and d) domestic crisis-intervention programs. Additional basic research is needed to more clearly delineate the causes of homicide so that effective preventive strategies can be implemented.

- References
- 1. Federal Bureau of Investigation. Uniform crime reports: crime in the United States 1981. Washington, D.C.: United States Department of Justice, 1982.
- 2. CDC. Unpublished data.
- 3. Jason J, Strauss LT, Tyler CW. A comparison of primary and secondary homicide in the United States. Am J Epidemiol (In press)
- Berardo FM. Symposium: Violence and the family. Journal of Marriage and the Family 1971;33:623-731.





\*These data represent the distributions of specified circumstances for only the first specified victim reported for each homicide incident.

†Based on 69,890 homicides, excluding 1,041 first specified victims of unknown age.

Homicide - Continued

- 5. Gelles RJ. Violence in the family: a review of research in the 70's. Journal of Marriage and the Family 1980;42:873-5.
- 6. Gibbons TCN. Violence in the family. Med Leg J 1975;45:76-88.
- Straus MA. Social stress and marital violence in a national sample of American families. Ann NY Acad Sci 1980;347:229-50.

# **Current Trends**

# Urban Rat Control — United States, Second Quarter, Fiscal Year 1982

During the second quarter of fiscal year 1982, 44 urban rat control programs identified 825 environmentally improved blocks<sup>\*</sup> (EIB) and achieved maintenance status in an additional 706 blocks (Table 5).<sup>†</sup>

Urban rat control programs provide a set of services—resident education, code enforcement, improved municipal services, neighborhood cleanup, and supplemental rat killing—designed to eliminate the environmental conditions that support rat infestations. During the quarter, these services are provided to over 2 million people living in almost 14,000 blocks.

Since 1969, urban rat control programs have served approximately 9.2 million people in over 61,000 blocks. As a result of program efforts, 7.9 million people now live in environmentally improved and rat-free neighborhoods.

Reported by Environment Health Svcs Div, Center for Environmental Health, CDC.

\*Blocks that have limited environmental deficiencies and are essentially rat free.

<sup>†</sup>Blocks that have remained in maintenance for at least 1 year and no longer require intensive rat control efforts.

Program community		Targo	Environmentally improved blocks*			
	Total	In attack phase	In maintenance phase		New this	
			< 12 months	$\geq$ 12 months		Cumulative
REGION I						_
Bridgeport	478	240	223	15	59	1,213
Hartford	220	120	85	15	0	0
Previously reporting programs	258	120	138	0	59	372
REGION II						
Atlantic City	3,395	1,241	993	759	29	5,670
Camden	202	17	78	32	0	Ō
Jersey City	332	134	60	38	0	119
Newark	183	51	94	38	0	260
New York City	174	16	24	9	27	170
Rochester	1,134	412	292	430	0	1,219
Yonkers	174	76	71	27	0	494
Aguadilla, P.R.	80	60	20	0	02	145
Arecibo, P.R.	199	143	50	6	2	256
Guayama, P.R.	102	36	66	0	0	291
Mayaguez, P.R.	176	121	55	0	0	40
Ponce, P.R.	155	67	72	16	0	239
San Juan, P.R.	226	39	23	62	0	378
Previously reporting programs	258	69	88	101	0	405

# TABLE 5. Status of target-area blocks in Urban Rat Control Programs, second quarter, fiscal year 1982 (January 1-March 31, 1982)

#### MMWR

## Urban Rat Control - Continued

TABLE 5. Status of target-area blocks in Urban Rat Control Programs, second quarter, fiscal year 1982 (January 1-March 31, 1982) (Continued)

Program community		Targ	Environmentally improved blocks*			
	Total	In attack phase	In maintenance phase		New	
			< 12 mont	hs $\ge$ 12 months	this quarter	Cumulative
REGION III						1,654
"War on Rats"	2,421	1,063	704	358	119	8,272
Chester	852	354	250	67	63	1,385
N.E. Pa. V.C. Assn. <sup>†</sup>	160	57	60	43	0	116
Philadelphia	526	207	84	120	5	1,369
Pittsburgh	883	445	310	128	51	1,697
Previously reporting programs					<b>!</b>	3,705
REGION IV	3,092	1.471	1,088	533	352	8.729
Tuscaloosa	302	71	209	22	56	147
Miami	1,336	672	574	90	179	1.373
Pensacola	150	87	63	0	33	439
Atlanta, Ga.§	491	373	89	29	Ō	0
Lexington	189	37	6	146	5	128
Louisville	407	190	57	160	72	842
Memphis	217	41	90	86	7	599
Previously reporting programs			•••			5,201
,	1,936	816	853	267	142	5.839
REGION V	476	206	241	207	9	24
Chicago	192	208	63	125	57	132
Peoria	132	46	82	10	31	726
Akron	115	40	102	12	Ő	182
Barberton	83	32	51	0	29	229
Cincinnati	285	222	63	ŏ	16	762
Cleveland			63	51	0	385
Columbus	180	66	102	0	ŏ	200
Toledo	138	36		40	ŏ	200
Youngstown	194	93	61 25	40	ŏ	20
Milwaukee	135	110	25	U	U	3,172
Previously reporting programs			•••••			•
REGION VI	845	489	255	101	0	7,039
New Orleans	301	87	136	78	0	3,139
Houston	544	402	119	23	0	2,356
Previously reporting programs						1,544
REGION VII	466	79	328	59	92	4,404
Kansas City, Mo.	100	14	86	0	24	771
St. Louis	244	41	147	56	0	1,168
Omaha	122	24	95	3	68	828
Previously reporting programs						. 1,637
REGION IX	362	131	211	20	32	1,875
Los Angeles	61	15	32	14	õ	504
Oakland	162	62	94	6	17	304
San Francisco	139	54	85	ŏ	15	396
Previously reporting programs				-		671
				i	•••••	
Region X						830
Previously reporting programs						. 830
Total	12,995	5,530	4.655	2,112	825	43.871

\*Contiguous blocks where maintenance has been achieved and sustained for a minimum of 12 months. These blocks are no longer part of the approved project target area.

<sup>†</sup>Northeastern Pennsylvania Vector Control Association. Serves Lackawanna and Luzerne counties and the cities of Nanticoke, Wilkes-Barre, and Hazleton. §Target-area blocks are confined to public housing projects.

The Morbidity and Mortality Weekly Report is prepared by the Centers for Disease Control, Atlanta, Georgia, and distributed by the National Technical Information Service, Springfield, Virginia. The data in this report are provisional, based on weekly telegrams to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday.

The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Such reports and any other matters pertaining to editorial or other textual considerations should be addressed to: ATTN: Editor, *Morbidity and Mortality Weekly Report*, Centers for Disease Control, Atlanta, Georgia 30333.

☆U.S. Government Printing Office: 1982-740-185/969 Region IV

### U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE / CENTERS FOR DISEASE CONTROL ATLANTA, GEORGIA 30333 OFFICIAL BUSINESS

Director, Centers for Disease Control William H. Foege, M.D. Director, Epidemiology Program Office Philip S. Brachman, M.D. Editor Michael B. Gregg, M.D. Mathematical Statistician Keewhan Choi, Ph.D. Assistant Editor Karen L. Foster, M.A. Postage and Fees Paid U.S. Department of HHS HHS 396

> THIRD CLASS BLK. RT.

> > 2



S 6HCRH3MCDJ73 8129 JOSEPH MC DADE PHD LEGIONNAIRE ACTIVITY LEPROSY & RICKETTSIAL BR VIROLOGY DIV, CID 7-85